Genome&Company Inc
KOSDAQ:314130
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genome&Company Inc
KOSDAQ:314130
|
KR |
|
Amphastar Pharmaceuticals, Inc
NASDAQ:AMPH
|
US |
|
B
|
Bed Bath & Beyond Inc
F:OVER
|
US |
Intrinsic Value
The intrinsic value of Genome&Company Inc (314130) under the Base Case is 1 546.38 KRW per share. Compared with the current market price of 3 905 KRW, the stock appears Overvalued by 60% .
The intrinsic value is calculated using the DCF method. The model assumes revenue grows about 30% a year over the next five years, less than a third of its five-year pace of 177%. Net margin ends at -100% by 2036, above its five-year average of -1672%. The forecast years subtract value, so the estimate rests entirely on the years after 2036.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Genome&Company Does
Genome&Company is a South Korean biotech company focused on the microbiome, the community of bacteria that live in and on the human body. It develops drug candidates and related technologies aimed mainly at cancer treatment, especially therapies that try to improve how patients respond to immuno-oncology drugs. The company also works on probiotic and skin-microbiome products through partnerships and product development.
- Headquarters
- Korea KR
- Employees
- 97
- IPO date
- Dec 26, 2018
Earnings Waterfall
Genome&Company Inc
The intrinsic value for Genome&Company Inc (314130) under the Base Case is 1 546.38 KRW.
Compared with the current market price of 3 905 KRW, the stock appears Overvalued by 60% .